By Blake Brittain (Reuters) - Biotech company Alnylam Pharmaceuticals Inc filed new lawsuits on Friday against Pfizer Inc (NYSE:PFE) and Moderna (NASDAQ:MRNA) Inc in Delaware...
BEIJING (Reuters) -Vaccine maker Moderna (NASDAQ:MRNA) Inc said on Friday it was looking for opportunities in China after confirming that it had registered a legal entity in the...
By Bhanvi Satija and Pratik Jain (Reuters) -Contract drug manufacturer Catalent (NYSE:CTLT) Inc on Friday slashed its full-year forecasts for profit and sales and delayed its...
(Wednesday market open) Investors seeking distraction from the ticking debt ceiling countdown clock get some this afternoon in the form of Federal Reserve meeting minutes and...
This week will be extremely busy as we have an FOMC decision, the nonfarm payroll report, peak earnings season, all while Wall Street keeps an eye on the banking industry to see if...
May is expected to be another volatile month on Wall Street. Investor focus will be on the Federal Reserve’s policy meeting, the monthly jobs report, inflation data, more...
Moderna, Inc. is a biotechnology company. The Company is focused on developing messenger ribonucleic acid (mRNA) therapeutics and vaccines. It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range spectrum of diseases. The Company's products include Spikevax, the Moderna COVID-19 vaccine (mRNA-1273), a bivalent vaccine targeting the BA.1 Omicron variant, combined with Spikevax (mRNA-1273.214), and bivalent vaccine targeting the BA.4/BA.5 Omicron variants combined with Spikevax (mRNA-1273.222). It has a development pipeline of 45 development candidates across its 48 development programs, of which 38 are in clinical studies.
| Average | 211.94 (+64.91% Upside) |
| High | 430.00 |
| Low | 93.00 |
| Price | 128.52 |
| No. of Analysts | 22 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Sell | Sell |
| Technical Indicators | Sell | Strong Sell | Strong Sell | Sell | Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Sell | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 124.37 | 125.04 | 123.30 | +1.00 | +0.81% | 24.25M | NASDAQ | |||
| 1.43 | 1.58 | 1.39 | -0.120 | -7.74% | 512.31K | NASDAQ | |||
| 1.01 | 1.04 | 0.991 | 0.00 | 0.00% | 844.01K | NASDAQ | |||
| 1.20 | 1.24 | 1.12 | +0.080 | +7.14% | 85.26K | NASDAQ | |||
| 2.54 | 2.54 | 2.54 | +0.38 | +17.59% | 100.00 | OTC Markets | |||
| 1.59 | 1.70 | 1.58 | -0.08 | -4.79% | 50.78K | NASDAQ | |||
| 293.96 | 294.98 | 275.76 | +0.17 | +0.06% | 3.68M | NASDAQ | |||
| 34.53 | 35.30 | 33.25 | +1.93 | +5.92% | 17.05M | NASDAQ | |||
| 19.50 | 19.50 | 19.01 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 74.69 | 75.78 | 70.20 | -16.21 | -17.83% | 19.65M | NASDAQ | |||
| 19.76 | 20.12 | 19.47 | -0.20 | -1.00% | 51.05K | NYSE | |||
| 15.80 | 16.93 | 13.16 | +2.88 | +22.29% | 49.66M | NYSE | |||
| 3.15 | 3.21 | 2.63 | +0.310 | +10.92% | 10.69M | NASDAQ | |||
| 10.37 | 10.80 | 10.26 | -0.16 | -1.52% | 273.94K | NASDAQ | |||
| 6.43 | 6.44 | 5.96 | +0.460 | +7.71% | 58.44K | NASDAQ |